211 related articles for article (PubMed ID: 30008882)
1. A meta-analysis of transcriptome datasets characterizes malignant transformation from melanocytes and nevi to melanoma.
Ortega-Bernal D; La Rosa CHG; Arechaga-Ocampo E; Alvarez-Avitia MA; Moreno NS; Rangel-Escareño C
Oncol Lett; 2018 Aug; 16(2):1899-1911. PubMed ID: 30008882
[TBL] [Abstract][Full Text] [Related]
2. The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
Maurus K; Hufnagel A; Geiger F; Graf S; Berking C; Heinemann A; Paschen A; Kneitz S; Stigloher C; Geissinger E; Otto C; Bosserhoff A; Schartl M; Meierjohann S
Oncogene; 2017 Sep; 36(36):5110-5121. PubMed ID: 28481878
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of lncRNAs and predicted target genes in normal mouse melanocytes and B16 cells.
Ji K; Zhang J; Fan R; Yang S; Dong C
Exp Dermatol; 2018 Nov; 27(11):1230-1236. PubMed ID: 30099777
[TBL] [Abstract][Full Text] [Related]
4. Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation.
Houghton AN; Albino AP; Cordon-Cardo C; Davis LJ; Eisinger M
J Exp Med; 1988 Jan; 167(1):197-212. PubMed ID: 2891780
[TBL] [Abstract][Full Text] [Related]
5. cDNA-array profiling of melanomas and paired melanocyte cultures.
Mischiati C; Natali PG; Sereni A; Sibilio L; Giorda E; Cappellacci S; Nicotra MR; Mariani G; Di Filippo F; Catricalà C; Gambari R; Grammatico P; Giacomini P
J Cell Physiol; 2006 Jun; 207(3):697-705. PubMed ID: 16523488
[TBL] [Abstract][Full Text] [Related]
6. Malignant melanoma and nevocellular nevi. Histogenesis and relationships. Fluorescence-microscopic and catamnestic photographic studies.
Paul E
Norm Pathol Anat (Stuttg); 1984; 48():1-112. PubMed ID: 6701085
[TBL] [Abstract][Full Text] [Related]
7. Identification of prognostic biomarkers for malignant melanoma using microarray datasets.
Lin G; Yin G; Yan Y; Lin B
Oncol Lett; 2019 Nov; 18(5):5243-5254. PubMed ID: 31620197
[TBL] [Abstract][Full Text] [Related]
8. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.
Hoek K; Rimm DL; Williams KR; Zhao H; Ariyan S; Lin A; Kluger HM; Berger AJ; Cheng E; Trombetta ES; Wu T; Niinobe M; Yoshikawa K; Hannigan GE; Halaban R
Cancer Res; 2004 Aug; 64(15):5270-82. PubMed ID: 15289333
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatics Analysis Identifies MicroRNAs and Target Genes Associated with Prognosis in Patients with Melanoma.
Li Q; Zhang LY; Wu S; Huang C; Liu J; Wang P; Cao Y
Med Sci Monit; 2019 Oct; 25():7784-7794. PubMed ID: 31621692
[TBL] [Abstract][Full Text] [Related]
10. Identification of epigenetically altered genes and potential gene targets in melanoma using bioinformatic methods.
Duan H; Jiang K; Wei D; Zhang L; Cheng D; Lv M; Xu Y; He A
Onco Targets Ther; 2018; 11():9-15. PubMed ID: 29302192
[TBL] [Abstract][Full Text] [Related]
11. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
12. Intercellular adhesion molecule 1 (ICAM-1) and bcl-2 are differentially expressed in early evolving malignant melanoma.
Collins KA; White WL
Am J Dermatopathol; 1995 Oct; 17(5):429-38. PubMed ID: 8599446
[TBL] [Abstract][Full Text] [Related]
13. Melanocyte-specific immune response in a patient with multiple regressing nevi and a history of melanoma.
Speeckaert R; van Geel N; Luiten RM; van Gele M; Speeckaert M; Lambert J; Vermaelen K; Tjin EP; Brochez L
Anticancer Res; 2011 Nov; 31(11):3697-703. PubMed ID: 22110189
[TBL] [Abstract][Full Text] [Related]
14. Melanocytes, moles and melanoma--a study on UV effects.
Stierner U
Acta Derm Venereol Suppl (Stockh); 1991; 168():1-31. PubMed ID: 1814138
[TBL] [Abstract][Full Text] [Related]
15. Nevi, other than dysplastic and Spitz nevi.
Cochran AJ; Bailly C; Paul E; Dolbeau D
Semin Diagn Pathol; 1993 Feb; 10(1):3-17. PubMed ID: 8506415
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of melanocytic lesions.
Seykora JT; Jih D; Elenitsas R; Horng WH; Elder DE
Am J Dermatopathol; 2003 Feb; 25(1):6-11. PubMed ID: 12544092
[TBL] [Abstract][Full Text] [Related]
17. Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence.
Huang JM; Chikeka I; Hornyak TJ
Dermatol Clin; 2017 Jan; 35(1):85-93. PubMed ID: 27890240
[TBL] [Abstract][Full Text] [Related]
18. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.
Wang W; Edington HD; Rao UN; Jukic DM; Wang H; Shipe-Spotloe JM; Kirkwood JM
J Invest Dermatol; 2008 Aug; 128(8):1997-2002. PubMed ID: 18305569
[TBL] [Abstract][Full Text] [Related]
19. Tumor progression in the human melanocytic system.
Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
[TBL] [Abstract][Full Text] [Related]
20. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
